.png)
About.
Advanced Respiratory Technologies
Advanced Respiratory Technologies is developing the next generation of artificial lungs for patients with chronic respiratory disease. Our extracorporeal life support (ECLS) system is different than traditionally known artificial lung devices, helping to redefine the way chronic respiratory disease is managed. Our system is highly mobile, lightweight, compact, and reduces patient complications by eliminating the need for systemic anticoagulation. Our ECLS technology reduces high ICU care costs, allows for complication free transport, and helps patients return home to their lives faster. This innovative Pulmonary Assist System device runs off of battery and lowers potential blood damage and coagulation for patients with chronic respiratory disease.
How Does It Work?
Our lightweight (3.2 kg) Pulmonary Assist System is wearable, compact, and runs off of battery. This device is worn at waist level, and our oxygenator is designed to provide peak performance for an extended period of time, with a disposables durability life of about 2-3 months before needing to be replaced. Traditional ECLS systems are too large for independent mobility, require replacing in about 2-3 weeks, and are prone to rapid clotting and failure. Our Pulmonary Assist System's unique design and coatings reduces the patient's risk of blood damage and coagulation. ART's innovative device is engineered to minimize the patient's risk for blood damage, ensuring durability and the safety of patients.
​
Patent #-US 10,251,989 B2 & EP 3 129 080 B1
Our Vision
Chronic respiratory disease affects 15 million patients in the United States, with 200,000 recorded deaths on an annual basis. A wearable, more easily managed ECLS system is vital to the hundreds of thousands of patients who struggle with chronic lung disease in the United States. Our system will reduce ICU care costs, repeat visits to the ER, and ICU admissions overall. ART's PAS will also enable patients to be transported to more specialized hospitals or care units, and helps patients live a relatively normal life while waiting for lung transplants or as an alternative to lung transplant
Patent #-US 10,251,989 B2 & EP 3 129 080 B1
Our Progress
Advanced Respiratory Technologies has successfully produced a fully functioning 3rd generation prototype with bench and pre-clinical studies backing our progress. We have raised roughly $7.45MM in non-dilutive NIH and $14.58MM in Non-dilutive DOD funds to support the PAS development. This funding has led to over 10 publications and 2 issued patents. As ART moves toward clinical translation of its products, we look forward to discussing new opportunities with potential investors, partners, and stakeholders.
Advanced Respiratory Technologies (ART) has raised roughly $22 million in grant funding, has over 10 publications and 2 issued patents. Our pulmonary assist system is designed to change the future of chronic lung disease, and is at the forefront of innovative solutions, with a clear vision for continued growth and advancement.
Let’s Work Together
Get in touch so we can start working together.
